Lin Zhi,Matthew P. Grote,Raja K. Reddy,Wenyu Li,William Craigo
申请号：
US16323508
公开号：
US20190194143A1
申请日:
2017.08.15
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia.
